updated data with larotrectinib in trk fusion-positive solid tumors
Published 4 years ago • 380 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:06
dr subbiah on outcomes with larotrectinib in trk fusion–positive solid tumors
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
1:06
updated response findings with larotrectinib in trk cancers
-
3:18
larotrectinib in adult and pediatric patients with trk fusion-positive primary cns tumors
-
0:39
larotrectinib is well-tolerated in metastatic solid tumors
-
0:54
efficacy results for loxo-101 in trk fusion cancers
-
4:25
updated data for larotrectinib
-
4:36
trk inhibition: personal experience with larotrectinib
-
6:03
larotrectinib in ntrk fusion-positive lung cancer
-
4:16
analyzing response rates with larotrectinib
-
6:47
efficacy of trki–larotrectinib among tumor types
-
1:29
dr. demetri on larotrectinib in trk-fusion gi cancers
-
2:14
treatment options for ntrk fusion–positive mcrc
-
6:51
entrectinib as treatment for ntrk-positive solid tumors
-
0:52
the impact of trk inhibitor loxo-101 (larotrectinib) on patients with trk fusion cancers
-
3:21
drawing larotrectinib data from different tumor types
-
1:13
larotrectinib in patients with trk fusion salivary gland tumours
-
3:20
approaching treatment for trk fusion–positive cancers